Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes

Clinical Chemistry

Volumn 49, Issue 5, 2003, Pages 752-760

  Poon, Terence C W ^a   Yip, Tai Tung ^b   Chan, Anthony T C ^a   Yip, Christine ^b   Yip, Victor ^b   Mok, Tony S K ^a   Lee, Conrad C Y ^a   Leung, Thomas W T ^a   Ho, Stephen K W ^a   Johnson, Philip J ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ANION EXCHANGE CHROMATOGRAPHY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; GENE CLUSTER; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MASS SPECTROMETRY; POSTOPERATIVE PERIOD; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SERUM; VALIDATION PROCESS;

CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MOLECULAR WEIGHT; PROTEIN ARRAY ANALYSIS; PROTEOME; SENSITIVITY AND SPECIFICITY;

EID: 0242417513     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.5.752     Document Type: Article

References (25)

1. Johnson PJ. The role of serum α-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-59.
2. Johnson PJ, Williams R. Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 1987;4:140-7.
3. Poon TCW, Johnson PJ. Proteome analysis and its impact on the discovery of serological tumor markers. Clin Chim Acta 2001;313:231-9.
4. Lee KH. Proteomics: a technology-driven and technology-limited discovery science. Trends Biotechnol 2001;19:217-22.
5. Tsugita A., Kawakami T, Uchida T, Sakai T, Kamo M, Matsui T, et al. Proteome analysis of mouse brain: two-dimensional electrophoresis profiles of tissue proteins during the course of aging. Electrophoresis 2000;21:1853-71.
6. Fountoulakis M, Berndt P, Boelsteri UA, Crameri F, Winter M, Albertini S, et al. Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis 2000;21:2148-61.
7. Jung E, Heller M, Sanchez JC, Hochstrasser DF. Proteomics meets cell biology: the establishment of subcellular proteomes. Electrophoresis 2000;21:3369-77.
8. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993;7:576-80.
9. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-92.
10. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
11. Petricoin EF III, Ardekani AM, Hitt AB, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
12. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
13. Srinivas PR, Sdvastava S, Hanash S, Wright GL Jr. Proteomics in early detection of cancer. Clin Chem 2001;47:1901-11.
14. Poon TCW, Chan ATC, Zee B, Ho SKW, Mok TSK, Leung TWT, et al. Application of classification tree and neural network algorithm to the identification of serological liver marker profiles in the diagnosis of hepatocellular carcinoma. Oncology 2001;61:275-83.
15. Xu Y, Selaru FM, Yin J, Zou TT, Shustova V, Mori Y, et al. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer. Cancer Res 2002;62:3493-7.
16. Johnson PJ, Leung N, Cheng P, Welby C, Leung T, Lau WY, et al. 'Hepatoma-specific' αfetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 1997;75:236-40.
17. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
18. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
19. Carulli JP, Artinger M, Swain PM, Root CD, Chee L, Tulig C, et al. High throughput analysis of differential gene expression. J Cell Biochem 1998;Suppl 30-31:286-96.
20. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 2001;98:15149-54.
21. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
22. Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, Ng IOL, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002;62:4711-21.
23. Liotta LA, Kohn EC, Petricoin EF III. Clinical proteomics: personalized molecular medicine. JAMA 2001;286:2211-4.
24. Cunningham MJ. Genomics and proteomics: the new millennium of drug discovery and development. J Pharmacol Toxicol Methods 2000;44:291-300.
25. Fung ET, Enderwick C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques 2002;Suppl 32:534-41.